Compare BridgeBio Pharma Inc (BBIO) vs MakeMyTrip Ltd (MMYT) Price & Performance

BridgeBio Pharma (BBIO) trades at $84.57, down slightly by 0.12% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth driven by Attruby sales, though it missed EPS estimates. With a high P/S ratio of 22.77 and negative profitability metrics, the stock is priced for future growth, supported by strong analyst buy ratings and a $104.56 consensus price target.

The outlook hinges on successful product launches and regulatory approvals, with three potential launches expected within 12 months offering significant upside. Key risks include persistent cash burn, high debt, and execution challenges in bringing new treatments to market, which could pressure the stock if milestones are missed.

MakeMyTrip (MMYT) trades at $60.70, down 0.34% with a bullish technical signal supported by moving averages. The company reported strong Q1 2027 earnings with revenue growth in hotels and packages offsetting air-ticketing softness. Analysts maintain a 72.7% buy rating with a 34.1% upside target. Recent financials show $978M revenue and $95M net income for 2025, though 2026 projections indicate margin compression.

The stock presents growth potential driven by travel recovery and platform diversification, but faces risks from geopolitical disruptions, fuel costs, and rising debt levels. Current valuation metrics (P/E 267, P/S 6.07) suggest premium pricing requiring sustained execution. Institutional sentiment remains positive despite recent selling by Boston Common Asset Management.